Current strategies and future directions in the treatment of age-related macular degeneration
10.3980/j.issn.1672-5123.2026.1.10
- VernacularTitle:ARMD治疗的当前策略与未来方向
- Author:
Jian XU
1
;
Jie WANG
1
;
Haixin FU
1
;
Chaopeng LI
1
Author Information
1. Department of Ophthalmology, the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China; Department of Ophthalmology, Huai'an Hospital, Huai'an 223200, Jiangsu Province, China
- Publication Type:Journal Article
- Keywords:
age-related macular degeneration(ARMD);
multi-targeted therapy;
anti-vascular endothelial growth factor(VEGF)combination therapy
- From:
International Eye Science
2026;26(1):56-62
- CountryChina
- Language:Chinese
-
Abstract:
Age-related macular degeneration(ARMD)is a progressive visual impairment fundus disease that frequently occurs in individuals aged >55 years. The main risk factors are aging, long-term smoking, genetics, and racial differences. Pathogenesis includes abnormal function of the retinal pigment epithelium, damaged blood-retinal barrier, and abnormal immune function. Currently, intravitreal injection(IVI)of anti-vascular endothelial growth factor(VEGF)drugs is the preferred treatment option for ARMD in clinical practice. However, it also faces challenges such as repeated treatments, high medical costs, and poor patient compliance. The predicament in the treatment of ARMD has given rise to several new treatment options. This article aims to review the treatment methods and progress of dry ARMD and wet ARMD, providing new ideas for addressing the limitations of the current clinical anti-VEGF treatment.
